EBDLR v2.0 – it is lightweight, portable, and budget-friendly solution
to fight acute liver failure.
Acute Liver Failure (ALF) is a life-threatening illness with a high mortality rate of up to 40-50%. It can progress rapidly, with liver failure developing within days to weeks after the onset of symptoms.
Unfortunately, liver transplant surgery is currently the only available treatment, but it's expensive and constrained by limited organ availability.
ALF can have multiple causes, including drug toxicity, hepatitis infections, poison consumption, and other conditions.
The EBDLR v2.0 is a state-of-the-art device built specifically to supplement the liver and enable it to regenerate itself with the support of the device.
KNOW MOREThe Pre-clinical studies have demonstrated promising results in rescuing subjects with ALF.
KNOW MOREYkrita Lifesciences has filed three patents for the EBDLR System in India, the PCT, and the USPTO, emphasizing the device's innovative nature and potential life-saving impact.
KNOW MORE
CEO and Director- Clinical & Biological Sciences
Advisor- Engineering and Design
Director Commercial, Legal and Administration
Chief Quality Officer
Project Head - Clinical Research & Development
Project Head - Engineering & Development
Project Engineer
Fabrication Engineer
Industrial Designer
Design Engineer
Fluid Mechanics Engineer
Embedded Engineer
Biomedical Engineer
Senior Research Executive
Senior Research Executive
Senior Research Executive
Senior Research Executive
Junior Research Executive
Junior Research Executive
Junior Research Executive
Senior Executive - Finance & Accounting
Office & Accounting Executive
Technical Assistant
